Variation in the management of thyroid cancer

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 5, 2013, Pages 2001-2008

  Haymart, Megan R ^a,b,d   Banerjee, Mousumi ^b   Yang, Di ^b   Stewart, Andrew K ^f   Sisson, James C ^d   Koenig, Ronald J ^a   Doherty, Gerard M ^e   Griggs, Jennifer J ^b,c  

^a Division of Metabolism Endocrinology and Diabetes   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d Boston University ^*  (United States)

^e BOSTON UNIVERSITY   (United States)

^f AMERICAN COLLEGE OF SURGEONS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RADIOACTIVE IODINE; THYROID HORMONE; THYROTROPIN;

ADULT; ARTICLE; CANCER REGISTRY; CANCER RESEARCH; CANCER SIZE; CANCER THERAPY; CLINICAL PRACTICE; COHORT ANALYSIS; ECHOGRAPHY; FEMALE; HEALTH CARE SURVEY; HORMONE SUBSTITUTION; HUMAN; LONG TERM CARE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MALE; PHYSICIAN; POSTOPERATIVE CARE; PRIORITY JOURNAL; THYROID CANCER; THYROID SURGERY; THYROTROPIN BLOOD LEVEL; UNITED STATES;

ADULT; COMBINED MODALITY THERAPY; ENDOCRINOLOGY; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; IODINE RADIOISOTOPES; LYMPH NODE EXCISION; MALE; MEDICAL ONCOLOGY; MEDICAL STAFF, HOSPITAL; MIDDLE AGED; NUCLEAR MEDICINE; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; RADIOPHARMACEUTICALS; SPECIALTIES, SURGICAL; THYROID NEOPLASMS; UNITED STATES; VOLUNTARY HEALTH AGENCIES;

EID: 84877712749     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-3355     Document Type: Article

References (24)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29.
2. National Cancer Institute. Commoncancer types. www.cancer.gov/ cancertopics/types/commoncancers. Accessed May 21, 2012.
3. National Cancer Institute. Surveillance Epidemiology and End Results. www.seer.cancer.gov. Accessed November 1, 2011.
4. Hay ID. Managing patients with a preoperative diagnosis of AJCC/UICC stage I (T1N0M0) papillary thyroid carcinoma: East versus West, whose policy is best? World J Surg. 2010;34:1291-1293.
5. Mazzaferri EL. What is the optimal initial treatment of low-risk papillary thyroid cancer (and why is it controversial)? Oncology (Williston Park). 2009;23:579-588.
6. Grant CS, Stulak JM, Thompson GB, Richards ML, Reading CC, Hay ID. Risks and adequacy of an optimized surgical approach to the primary surgical management of papillary thyroid carcinoma treated during 1999-2006. World J Surg. 2010;34:1239-1246.
7. Durante C, Attard M, Torlontano M, et al. Identification and optimal postsurgical follow-up of patients with very low-risk papillary thyroid microcarcinomas. J Clin Endocrinol Metab. 2010;95:4882- 4888.
8. Doi SA, Engel JM, Onitilo AA. Total thyroidectomy followed by postsurgical remnant ablation may improve cancer specific survival in differentiated thyroid carcinoma. Clin Nucl Med. 2010;35:396- 399.
9. Mendelsohn AH, Elashoff DA, Abemayor E, St John MA. Surgery for papillary thyroid carcinoma: is lobectomy enough? Arch Otolaryngol Head Neck Surg. 2010;136:1055-1061.
10. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19: 1167-1214.
11. Bilimoria KY, Bentrem DJ, Linn JG, et al. Utilization of total thyroidectomy for papillary thyroid cancer in the United States. Surgery. 2007;142:906-913; discussion 13 e1-2.
12. Haymart MR, Banerjee M, Stewart AK, Koenig RJ, Birkmeyer JD, Griggs JJ. Use of radioactive iodine for thyroid cancer. JAMA. 2011; 306:721-728.
13. Kim EY, Eisele DW, Goldberg AN, Maselli J, Kezirian EJ. Neck dissections in the United States from 2000 to 2006: volume, indications, and regionalization. Head Neck. 2011;33:768-773.
14. Dillman DA, ed. 2007 Mail and Internet Surveys: The Tailored Design Method, 2nd ed. New York, NY: Wiley, 2007.
15. Tuttle RM, Ball DW, Byrd D, et al. Thyroid carcinoma. J Natl Compr Canc Netw. 2010;8:1228-1274.
16. Bilimoria KY, Bentrem DJ, Ko CY, et al. Extent of surgery affects survival for papillary thyroid cancer. Ann Surg. 2007;246:375-381; discussion 81-84.
17. Greenberg CC, Lipsitz SR, Neville B, et al. Receipt of appropriate surgical care for Medicare beneficiaries with cancer. Arch Surg. 2011;146:1128-1134.
18. In H, Neville BA, Lipsitz SR, Corso KA, Weeks JC, Greenberg CC. The role of National Cancer Institute-designated cancer center status: observed variation in surgical care depends on the level of evidence. Ann Surg. 2012;255:890-895.
19. Jonklaas J, Sarlis NJ, Litofsky D, et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid. 2006;16:1229-1242.
20. Haymart M, Banerjee M, Yang D, et al. The relationship between extent of thyroid cancer surgery and use of radioactive iodine. Ann Surg. 2012;35:396-399.
21. Haymart MR, Banerjee M, Yang D, Stewart AK, Koenig RJ, Griggs JJ. The role of clinicians in determining radioactive iodine use for low-risk thyroid cancer. Cancer. 2013;119:259-265.
22. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA. 2006;295:2164-2167.
23. Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer. 2009;115: 3801-3807.
24. Hughes DT, Haymart MR, Miller BS, Gauger PG, Doherty GM. The most commonly occurring papillary thyroid cancer in the United States is now a microcarcinoma in a patient older than 45 years. Thyroid. 2011;21:231-236.